Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03681561 is registered in ClinicalTrials.gov with Veronika Bachanova as lead sponsor.

NCT NCT03681561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03681561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Nivolumab in Combination With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Lead sponsor
Veronika Bachanova
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 13, 2018
Completion date
July 31, 2027
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma